摘要
目的探讨前列地尔对缺血性脑卒中(Ischemic Stroke,IS)的临床疗效及其对脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)和基质金属蛋白酶9(matrix metalloproteinase 9,MMP-9)的影响。方法将2007-06-2012-07在我院就诊的80例IS患者按照入院顺序随机分为前列地尔治疗组和对照组各40例。对照组采用常规治疗,前列地尔治疗组在常规治疗基础上每天加用20μg前列地尔静滴治疗,持续14d。比较2组临床疗效、BDNF和MMP-9的变化。结果前列地尔组和对照组的总有效率分别为97.50%和80.00%;与治疗前相比,治疗后2组脑卒中量表(NIHSS)评分均显著下降(P<0.05),而日常生活自理能力量表(Activity of Daily Living Scale,ADL)评分则明显增高(P<0.05),经治疗2组BDNF含量均显著增加(P<0.05),而MMP-9则明显下降(P<0.05),前列地尔组上述指标的改善程度均明显高于对照组(P<0.05)。结论前列地尔能有效改善IS患者的临床症状,增加血浆BDNF水平及降低MMP-9含量可能是其治疗IS的可能作用机制。
Objective To observe the clinical effects of ProstaGlandinE1 （PGE1） and the influence on the BDNF and MMP-9 levels in patients with ischemie stroke. Methods Eighty cases enrolled in our hospital from July, 2007 June to 2012 July were randomly and equally divided into two groups： PGE1 group （n= 40） and control group （n= 40）. Patients from control group were given traditional medical treatment whereas patients from PGE1 group were also provided with 20μg PGE1 supplement daily. Patients from both groups were treated for 14 days and the clinical effects, BDNF and MMP-9 levels were compared. Results The clinical effective rate were 97.50% and 80.00%, respectively. As compared with control group, the NIHSS scores of PGE1 group significantly decreased （P〈0.05） while the ADL scores of it significantly increased （P%0.05）. After treatments, parameters of BDNF of two groups all significanlty increased （P〈0.05） but the MMP-9 levels all significanlty decreased （P〈0.05）. However, the improvement of PGE1 goup were significant more superior than that of control goup （P〈0.05）. Conclusion POE1 could improve the BDNF and MMP-9 levels of isehemic stroke, which is the potential mechanism of PGE1 ＇ s clinical effect.
出处
《中国实用神经疾病杂志》
2013年第24期13-16,共4页
Chinese Journal of Practical Nervous Diseases
